Immune Regulation announces positive results from Phase 1 clinical trial of PIN201104

Immune Regulation announces positive results from Phase 1 clinical trial of PIN201104

• Confirmed clean safety profile

• No serious or severe adverse effects

• Primary endpoints of safety and pharmacokinetic data achieved

Stevenage, UK, 26 November 2018 – Immune Regulation Ltd. (‘Immune Regulation’ or the ‘Company’, formerly known as Peptinnovate), a biopharmaceutical company developing “first in class” immune-resetting therapies for asthma and other inflammatory diseases, announces positive results from a Phase 1 study of its lead compound PIN201104 (‘1104).

Study C1104-001 was a First Time in Human, randomised, double blind, placebo controlled, parallel group study in healthy volunteers and patients with asthma to assess the safety, tolerability and pharmacokinetics of single ascending and repeat doses of ‘1104.

Menu